174607-68-2

Basic information

• Product Name: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol)
• Synonyms: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol);(R)-4-Benzyl Albuterol;Levalbuterol Related CoMpound F;(1R)-2-(tert-butylamino)-1-[3-(hydroxymethyl)-4-phenylmethoxyphenyl]ethanol
• CAS NO: 174607-68-2
• Molecular Formula: C₂₀H₂₇NO₃
• Molecular Weight: 329.43328
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 174607-68-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 510.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.120±0.06 g/cm3(Predicted)
• PKA: 13.97±0.20(Predicted)
• CAS DataBase Reference: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol)(CAS DataBase Reference)
• NIST Chemistry Reference: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol)(174607-68-2)
• EPA Substance Registry System: Levalbuterol Related Compound F (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl}-4-(phenylmethoxy)-1,3-benzenedimethanol)(174607-68-2)

Safety Data

• Hazardous Substances Data: 174607-68-2(Hazardous Substances Data)

Usage

Description

Levalbuterol Related Compound F (30 mg) (alpha-[(1,1-Dimethylethyl)aminomethyl-4-(phenylmethoxy)-1,3-benzenedimethanol) is a chemical compound derived from the precursor of Albuterol, a medication used for treating asthma and other respiratory conditions. It is characterized by its unique chemical structure, which includes a dimethylethylamino group and a phenylmethoxy group attached to a benzene ring.

Uses

Used in Pharmaceutical Industry:
Levalbuterol Related Compound F (30 mg) (alpha-[(1,1-Dimethylethyl)aminomethyl-4-(phenylmethoxy)-1,3-benzenedimethanol) is used as an intermediate in the synthesis of Albuterol, a medication for treating respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It helps in the development of more effective and safer drugs for respiratory ailments.
Used in Research and Development:
Levalbuterol Related Compound F (30 mg) (alpha-[(1,1-Dimethylethyl)aminomethyl-4-(phenylmethoxy)-1,3-benzenedimethanol) is utilized in research and development for studying its chemical properties, potential applications, and possible modifications to improve its therapeutic effects. Levalbuterol Related Compound F (30 mg) (alpha-[(1,1-Dimethylethyl)aminomethyl-4-(phenylmethoxy)-1,3-benzenedimethanol) can be further investigated for its potential use in the development of new drugs or drug delivery systems.

Upstream product

• 39235-60-4 4'-benzyloxy-3'-acetoxymethylacetophenone 
• 39235-61-5 4'-benzyloxy-3'-(acetoxymethyl)bromoacetophenone 
• 1005420-22-3 (R)-4-benzyl salbutamol formate 
• 1005420-21-2 4-nitro tartranilic acid salt of (R)-isomer of 4-benzyl salbutamol 

Downstream Products

• 324000-05-7 salbutamol sulphate 
• 50293-91-9 levosalbutamol hydrochloride 

Relevant articles and documents

Preparation method of leverbuterol and its salt

The invention provides a method for cheap and effective preparation of leverbuterol in industry. The method consists of: taking protected 4-hydroxy-3-hydroxymethyl acetophenone as the raw material to react with bromine to generate acyl or alkyl protected 4-hydroxy-3-hydroxymethyl bromoacetophenone, under in the presence of (1R, 2S)-(+)-indanol as a catalyst, using borane to conduct chiral reduction on carbonyl in the structural formula to obtain R configuration acyl or alkyl protected 4-hydroxy-3-hydroxymethyl alpha bromo phenethyl alcohol, then carrying out reaction with tert-butylamine to generate acyl or alkyl protected 4-hydroxy-3-hydroxymethyl phenylaminoethanol, and finally removing the acyl protecting group to obtain leverbuterol free alkali, and letting the free alkali and acid form a salt. The finished product has optical purity up to 99.9%, and no other chiral resolution way is needed for purification.

A PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

A process for the preparation of optically pure R (-) salbutamol of formula (6) and its pharmaceutically acceptable salts by using a (+) 4-nitro tartranilic acid as the resolving agent and a binary solvent system comprising alkyl acetate and C1 to C4 branched or normal chain alcohol for dissolution of the racemic mixture and resolving agent and purification of the 4-nitro tartranilic acid salt of R (-) salbutamol. 4-nitro tartranilic acid salt of R (-) salbutamol is converted into formic acid salt of R(-) 4-benzyl salbutamol followed by basification and debenzylation to form optically pure R(-) salbutamol. Optically pure (R) -salbutamol is obtained in good yield and high purity. The optically pure R(-) salbutamol is optionally converted into pharmaceutically acceptable salts.